Mibiton

Mibiton Foundation is a venture capital investment firm established in 1994 and located in The Hague, Netherlands. The firm focuses on investing in the healthcare, life sciences, and health tech sectors, actively contributing to the growth of the Dutch life sciences industry. Through its investments, Mibiton aims to support innovative companies and advancements within these fields.

Colja Laane

Chairman

Kees Recourt

Investment Director

2 past transactions

BioConnection

Secondary Market in 2022
BioConnection is a European company specializing in the development and manufacturing of injectable biopharmaceutical products. It offers contract manufacturing services to small biopharmaceutical companies, providing access to both small-scale clinical batch production and large-scale commercial manufacturing facilities. The company is equipped with filling and freeze-drying technology and supports clients with sterile drug product development, process validation, and analytical services. BioConnection's extensive network of skilled suppliers and collaborators, including partnerships with experienced organizations, enhances its ability to deliver reliable solutions for clients focusing on personalized medications and clinical trials. By serving as an independent intermediary, BioConnection simplifies the process for companies that may lack the resources or expertise for comprehensive clinical development, ensuring efficient product delivery without the need for clients to seek multiple vendors.

Sirius Medical

Series A in 2020
Sirius Medical helps improve healthcare for cancer patients by developing medical devices that aid in surgical treatment. Their objective is to create intuitive and accurate gadgets that allow surgeons and radiologists to provide the finest treatment. Sirius Perception uses audio and visual feedback to provide real-time, directional advice for pinpointing tumors
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.